roxifiban has been researched along with xv 459 in 6 studies
| Studies (roxifiban) | Trials (roxifiban) | Recent Studies (post-2010) (roxifiban) | Studies (xv 459) | Trials (xv 459) | Recent Studies (post-2010) (xv 459) |
|---|---|---|---|---|---|
| 40 | 7 | 1 | 15 | 2 | 0 |
| Protein | Taxonomy | roxifiban (IC50) | xv 459 (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.0271 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.0271 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gretler, DD; Scarborough, RM | 1 |
| Kapil, R; Mousa, SA; Mu, DX | 1 |
| Christ, DD; Diamond, S; Gan, L; Mutlib, AE; Nemeth, G; Shockcor, J; Way, R | 1 |
| Cain, VA; Ebling, W; Fossler, MJ; Kornhauser, DM; Ma, S; Mondick, JT; Pieniaszek, HJ; Sy, SK | 1 |
| Barrett, JS; Ebling, WF; Fossler, MJ; Garner, D; Kornhauser, D; Ma, S; Mondick, J; Pieniaszek, HJ; Quon, CY | 1 |
| Barrett, YC; Davidson, AF; Olson, RE; Pieniaszek, HJ; Pinto, DJ; Reilly, TM; Walton, HL | 1 |
1 review(s) available for roxifiban and xv 459
| Article | Year |
|---|---|
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Design; Fibrinolytic Agents; Humans; Injections; Integrins; Molecular Mimicry; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms | 2000 |
2 trial(s) available for roxifiban and xv 459
| Article | Year |
|---|---|
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Amidines; Amino Acids; Area Under Curve; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hydrolysis; Isoxazoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs; Time Factors | 2002 |
Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers.
Topics: Administration, Oral; Aged; Amidines; Amino Acids; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Isoxazoles; Middle Aged; Models, Biological; Platelet Glycoprotein GPIIb-IIIa Complex; Prodrugs | 2002 |
3 other study(ies) available for roxifiban and xv 459
| Article | Year |
|---|---|
Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Topics: Administration, Oral; Amidines; Amino Acids; Animals; Bleeding Time; Disease Models, Animal; Dogs; Electroshock; Female; Femoral Artery; Humans; Injections, Intravenous; Isoxazoles; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1999 |
Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
Topics: Amidines; Amino Acids; Animals; Cardiovascular Agents; Chromatography, High Pressure Liquid; Dogs; Feces; Gas Chromatography-Mass Spectrometry; Humans; Isoxazoles; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thrombosis | 2000 |
A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.
Topics: Amidines; Amino Acids; Animals; Antibodies; Binding Sites; Humans; Isoxazoles; Linear Models; Rabbits; Radioimmunoassay | 2003 |